Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck’s presence in cardiovascular medicine as key products approach patent expirations. Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years. The...

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.

The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.

Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.

Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.

Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

Personalis has hired investment banks Centerview and TD Securities, along with law firm Cooley, to review its strategic options, according to a report in Street Insider.

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

Merck is back in focus as analysts refine their models, with bullish firms now setting price targets in a US$138 to US$155 range that sit above a refreshed fair value estimate of US$132.78 per share. These higher targets are being framed around updated earnings assumptions, views on the Q2 setup, and analysis of how Merck’s pipeline and regulatory backdrop could influence the stock’s risk and reward profile. Read on to see how to interpret these changing targets and follow the evolving Merck...

Merck (MRK) is approaching key pipeline catalysts with ISLEND and islatravir plus ulonivirine data t

While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.

While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.

Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.

The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.

It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.

It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.

Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.

Stock Market Today: The Dow Jones index rose Wednesday after a cool inflation reading. ASML stock jumped on earnings.

Merck stock popped Wednesday on the back of positive test results for a new treatment combo in a common form of lung cancer.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1%, and the actively tra

Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study. This is the first PD-1 inhibitor plus antibody drug conjugate regimen cleared for these patients regardless of cisplatin eligibility. The latest approval adds another indication for Merck's flagship oncology drug Keytruda. It reinforces the company’s presence in bladder...

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.

The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.